

Global Biosimilars Market - 2024-2033

<https://marketpublishers.com/r/G5286331A912EN.html>

Date: February 2026

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: G5286331A912EN

Abstracts

The Global Biosimilars Market was valued at US\$ 30.30 Billion in 2024 and is anticipated to reach US\$ 99.3 Billion by 2033, at a CAGR of 0.141 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Biosimilars Market.

This report delivers a comprehensive overview of the Global Biosimilars Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Biosimilars Market. The Global Biosimilars Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Global Biosimilars Market Scope:

By Drug Class

Monoclonal Antibodies (mAbs)

Tumor Necrosis Factor-Alpha (TNF-?) Inhibitors

Granulocyte Colony-Stimulating Factor (G-CSF)

Insulin

Erythropoietin

Human Growth Hormone

Follitropin

Interferons

Anti-Vascular Endothelial Growth Factor

Other Drug Classes

By Therapeutic Area

Oncology

Immunology & Autoimmune Diseases

Metabolic Diseases (including diabetes)

Neurology

Infectious Diseases

Rare Diseases

Others

By Manufacturing Modality

Mammalian Cell-Based Biosimilars

Microbial-Based Manufacturing

Plasma-Derived Manufacturing

Other Manufacturing Platforms

By Route of Administration

Intravenous

Subcutaneous

Intramuscular

Others

By End-User

Hospitals & Specialty Clinics

Infusion Centers

Specialty Pharmacies

Others

Key Players

Pfizer, Inc.

Amgen Inc.

Novartis AG (Sandoz division)

Samsung Bioepis Co., Ltd.

Celltrion, Inc.

Biocon Limited

Viartis Inc.

Teva Pharmaceutical Industries Ltd.

Boehringer Ingelheim International GmbH

Merck KGaA

F. Hoffmann-La Roche Ltd.

Dr. Reddy's Laboratories Ltd.

STADA Arzneimittel AG

Fresenius Kabi AG

Apotex Inc.

Major Highlights

This report delivers a comprehensive overview of the Global Biosimilars Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Biosimilars Market. The Global Biosimilars Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Government-Led Switching and Tender Policies Accelerating Biosimilars Adoption in Public Health Systems
 - 3.1.1.2. Patent Expiry Wave of Blockbuster Biologics Unlocking Multi-Billion-Dollar Biosimilars Entry Windows
 - 3.1.1.3. Hospital and Payer Cost-Containment Programs Prioritizing Biosimilars in Treatment Protocols
 - 3.1.2. Restraints
 - 3.1.2.1. Interchangeability and Physician Confidence Barriers Slowing Automatic Substitution
 - 3.1.2.2. High Analytical and Clinical Comparability Costs Limiting New Entrant Participation
 - 3.1.2.3. Complex Cold-Chain and Bioprocess Manufacturing Requirements Increasing Operational Risk
 - 3.1.3. Opportunity

3.1.3.1. Rapid Expansion of Biosimilars in Emerging Therapeutic Segments such as Ophthalmology and Rare Diseases

3.1.3.2. Strategic Licensing and Co-Development Agreements Between Innovators and Biosimilars Developers

3.1.3.3. Growth of Local Biomanufacturing Hubs in Asia and Latin America Supporting Export-Oriented Drug Class

3.1.4. Trends

3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter's Five Force Analysis – Global Biosimilars

4.2. Geopolitical & Supply Chain Exposure

4.3. Social & Patient-Centric Factors

4.4. Economic Factors

4.5. Pricing Analysis

4.6. Regulatory Analysis

4.7. Go-To-Market (GTM) Strategy

4.8. Innovation & R&D Trends

4.9. Sustainability and ESG Analysis

4.10. Biosimilars Ecosystem Participants

4.11. Buyer Decision Criteria & Adoption Drivers

4.12. DMI Opinion – Strategic Outlook for the Global Biosimilars Market

5. BY DRUG CLASS

5.1. Introduction

5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

5.1.2. Market Attractiveness Index, By Drug Class

5.2. Monoclonal Antibodies (mAbs)*

5.2.1. Introduction

5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

5.3. Tumor Necrosis Factor-Alpha (TNF-?) Inhibitors

5.4. Granulocyte Colony-Stimulating Factor (G-CSF)

5.5. Insulin

5.6. Erythropoietin

5.7. Human Growth Hormone

5.8. Follitropin

5.9. Interferons

5.10. Anti-Vascular Endothelial Growth Factor

5.11. Other Drug Classes

6. BY THERAPEUTIC AREA

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

6.1.2. Market Attractiveness Index, By Therapeutic Area

6.2. Oncology*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Immunology & Autoimmune Diseases

6.4. Metabolic Diseases (including diabetes)

6.5. Neurology

6.6. Infectious Diseases

6.7. Rare Diseases

6.8. Others

7. BY MANUFACTURING MODALITY

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality

7.1.2. Market Attractiveness Index, By Manufacturing Modality

7.2. Mammalian Cell-Based Biosimilars*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Microbial-Based Manufacturing

7.4. Plasma-Derived Manufacturing

7.5. Other Manufacturing Platforms

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8.1.2. Market Attractiveness Index, By Route of Administration

8.2. Intravenous *

8.2.1. Introduction

- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Subcutaneous
- 8.4. Intramuscular
- 8.5. Others

9. BY END-USER

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 9.1.2. Market Attractiveness Index, By End-User
- 9.2. Hospitals & Specialty Clinics*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Infusion Centers
- 9.4. Specialty Pharmacies
- 9.5. Others

10. BY REGION

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
 - 10.2.1. Introduction
 - 10.2.2. Key Region-Specific Dynamics
 - 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
 - 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
 - 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.2.8.1. US
 - 10.2.8.2. Canada
 - 10.2.8.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction
 - 10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.8.1. Germany

10.3.8.2. UK

10.3.8.3. France

10.3.8.4. Russia

10.3.8.5. Italy

10.3.8.6. Spain

10.3.8.7. Norway

10.3.8.8. Netherlands

10.3.8.9. Sweden

10.3.8.10. Denmark

10.3.8.11. Belgium

10.3.8.12. Switzerland

10.3.8.13. Austria

10.3.8.14. Poland

10.3.8.15. Finland

10.3.8.16. Rest of Europe

10.4. Latin America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.8.1. Brazil

10.4.8.2. Argentina

10.4.8.3. Rest of Latin America

10.5. Asia-Pacific

- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
- 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.5.8.1. China
 - 10.5.8.2. India
 - 10.5.8.3. Japan
 - 10.5.8.4. Australia
 - 10.5.8.5. South Korea
 - 10.5.8.6. New Zealand
 - 10.5.8.7. Indonesia
 - 10.5.8.8. Malaysia
 - 10.5.8.9. Philippines
 - 10.5.8.10. Singapore
 - 10.5.8.11. Thailand
 - 10.5.8.12. Vietnam
 - 10.5.8.13. Rest of Asia-Pacific
- 10.6. Middle East and Africa
 - 10.6.1. Introduction
 - 10.6.2. Key Region-Specific Dynamics
 - 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
 - 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
 - 10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.6.8.1. UAE
 - 10.6.8.2. Saudi Arabia
 - 10.6.8.3. South Africa
 - 10.6.8.4. Israel
 - 10.6.8.5. Egypt

- 10.6.8.6. Turkey
- 10.6.8.7. Qatar
- 10.6.8.8. Kuwait
- 10.6.8.9. Oman
- 10.6.8.10. Bahrain
- 10.6.8.11. Rest of Middle East and Africa

11. COMPETITIVE LANDSCAPE ANALYSIS

- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 11.4. Partner Identification Analysis
- 11.5. Investment & Funding Landscape
- 11.6. Strategic Alliances & Innovation Pipelines

12. COMPANY PROFILES

- 12.1. Pfizer, Inc.*
 - 12.1.1. Company Overview
 - 12.1.2. Product Portfolio
 - 12.1.3. Revenue Analysis
 - 12.1.4. Pricing Analysis
 - 12.1.5. SWOT Analysis
 - 12.1.6. Recent Developments
 - 12.1.6.1. Major Deals
 - 12.1.6.2. M&A
 - 12.1.6.3. Collaboration
 - 12.1.6.4. Acquisition
 - 12.1.6.5. Joint Ventures
 - 12.1.6.6. Innovations
 - 12.1.7. Recent News
 - 12.1.7.1. Events
 - 12.1.7.2. Conferences
 - 12.1.7.3. Symposia
 - 12.1.7.4. Webinars
- 12.2. Amgen Inc.
- 12.3. Novartis AG (Sandoz division)
- 12.4. Samsung Bioepis Co., Ltd.

- 12.5. Celltrion, Inc.
- 12.6. Biocon Limited
- 12.7. Viatris Inc.
- 12.8. Teva Pharmaceutical Industries Ltd.
- 12.9. Boehringer Ingelheim International GmbH
- 12.10. Merck KGaA
- 12.11. F. Hoffmann-La Roche Ltd.
- 12.12. Dr. Reddy's Laboratories Ltd.
- 12.13. STADA Arzneimittel AG
- 12.14. Fresenius Kabi AG
- 12.15. Apotex Inc. (LIST NOT EXHAUSTIVE)

13. GLOBAL BIOSIMILARS MARKET – RESEARCH METHODOLOGY

- 13.1. Research Data
 - 13.1.1. Secondary Data
 - 13.1.2. Primary Data
 - 13.1.3. CAGR Analysis
- 13.2. Market Size Estimation Methodology
 - 13.2.1. Bottom-Up Approach
 - 13.2.2. Top-Down Approach
- 13.3. Market Breakdown & Data Triangulation
- 13.4. Research Assumptions
- 13.5. Limitations

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Global Biosimilars Market - 2024-2033

Product link: <https://marketpublishers.com/r/G5286331A912EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5286331A912EN.html>